IL2 and renal cell adenocarcinoma: The impact of the immune contexture of concerned tumors considered as immunogenic, such as melanoma or renal cell cancer, in which the success of active IL-2, IFNα or TIL immunotherapy had been documented [35], [36], as well as tumors in which there is, so far, no success of these approaches [36], which leaves open the search for alternative novel immunotherapies.